Sanofi has committed to donate 100 million doses of hydroxychloroquine across 50 countries to support fight against Covid-19.
The company increased its production capacity by 50% and is making preparations to further boost production over the coming months.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
If ongoing clinical trials demonstrate hydroxychloroquine’s safety and efficacy in Covid-19, Sanofi will continue to donate the drug to governments and hospitals.
Sanofi CEO Paul Hudson said: “It is critical that international authorities, local governments, manufacturers, and all the other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it.
“If the trials prove positive, we hope our donation will play a critical role for patients.”
Meanwhile, the US National Institutes of Health started the ORCHID Study of hydroxychloroquine to treat adults hospitalised with Covid-19.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
